Steven Lubitz

Dr. Steven Lubitz is a physician-scientist and Director in Translational Medicine within the Cardiovascular and Metabolism group at Novartis, where he has worked since 2022. In this role, he leads cross-functional teams to design and implement clinical trials, integrating insights from preclinical science, data science, and commercial strategy. He earned his medical degree from the University of Michigan, completed internal medicine and cardiovascular training at Mount Sinai Hospital, and pursued electrophysiology training at Massachusetts General Hospital. He also holds a Master of Public Health from the Harvard T. H. Chan School of Public Health.

Prior to joining Novartis, Dr. Lubitz served as an Associate Professor at Harvard Medical School and as an electrophysiologist at Massachusetts General Hospital. He co-directed the Cardiovascular Genetics Program and led research initiatives focused on cardiovascular genetics, machine learning, and digital health. His work has been supported by the NIH, American Heart Association, Doris Duke Charitable Foundation, and industry sponsors. He played a leading role in studies such as VITAL-AF, GUARD-AF, and the Fitbit Heart Study, which explored new approaches to atrial fibrillation screening. He is committed to mentorship and collaborative translational research to reduce cardiovascular disease.